AGM.L

Applied Graphene Materials Plc
Applied Graphene - Update on Strategic Review & Other Matters
13th January 2023, 07:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 5953M
Applied Graphene Materials PLC
13 January 2023
 

This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").

13 January 2023

Applied Graphene Materials plc

("Applied Graphene Materials", the "Company" or the "Group")

Update on strategic review and other matters

The Board provides the following update in relation to the ongoing strategic review and other matters.

Strategic Review

The Company, in conjunction with Alvarez & Marsal Europe LLP as financial adviser, is continuing its discussions with various parties that have submitted non-binding indicative proposals for either the sale of the Group's trade and assets or of the shares in the Company's main operating subsidiary.

The Board had initially sought non-binding indicative proposals from interested parties with a view to completing a transaction by 31 January 2023. Completing a transaction on a solvent basis will, in all likelihood, require shareholder approval in a general meeting, as well as other regulatory approvals. Discussions with interested parties are ongoing and the Board is seeking to select a preferred party with whom to enter into legally binding contractual terms by 31 January 2023. The completion of any transaction will only take effect once those shareholder and regulatory approvals have been obtained and this will not take place before 31 January 2023.

The Board has also previously notified that 31 January 2023 would be the date on which the Group's working capital position is expected to become fully depleted. The Board has reviewed the Group's projected cash flows further and taken mitigating action where appropriate to reduce costs and maintain liquidity beyond 31 January 2023.

The Board now believes that, without any further funding (including, for example, any interim funding that, in all likelihood, will be required to progress a transaction with a preferred party to completion), the Company's available working capital will become fully depleted by 28 February 2023. 

As previously disclosed, the Board continues to take action to seek to protect the financial position of the Company, its shareholders and creditors in the event that the strategic review does not achieve a satisfactory result. In parallel with the strategic review, the process of statutory redundancy consultations with the Group's employees announced on 23 November 2022 is ongoing.

Current discussions with interested parties may be altered or terminated at any time and, accordingly, there can be no certainty that any final proposals will be made, nor as to the terms on which any such final proposals may be made. 

Annual Report and Accounts for the year ended 31 July 2022

The Board continues to work with its auditors, RSM UK Audit LLP, with a view to publishing the Company's annual report and accounts for the year ended 31 July 2022 ("FY22") by 31 January 2023, being the deadline for publication stipulated under the AIM Rules for Companies.

If the FY22 annual report and accounts are not published by the deadline, the Company's ordinary shares of two pence each ("Ordinary Shares") will be suspended from trading on AIM with effect from 1 February 2023 pending publication of the Company's FY22 annual report and accounts.

OTCQX Best Market US listing

The Ordinary Shares have, since 29 July 2021, also traded on the OTCQX Best Market in the United States. In order to reduce costs and continue to provide a facility for US-based shareholders to freely trade the Ordinary Shares, the Company has elected for its Ordinary Shares to be traded on the OTCQB Venture Market under the ticker symbol APGMF with effect from 17 January 2023.

The Board will continue to provide further updates as appropriate.

For further information, please contact:

Applied Graphene Materials  +44 (0) 1642 438 214

Adrian Potts, Chief Executive Officer

David Blain, Chief Financial Officer

Alvarez & Marsal Europe LLP +44 (0) 784 107 2042

Alex Baird  abaird@alvarezandmarsal.com

Singer Capital Markets  (Nominated Adviser and Joint Broker) +44 (0) 207 496 3000

Peter Steel / Oliver Platts

Allenby Capital Limited (Joint Broker) +44 (0) 203 328 5656

Nick Athanas / Dan Dearden-Williams (Corporate Finance)

Hudson Sandler  +44 (0) 207 796 4133

Nick Lyon / Emily Dillon

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDGPUWWGUPWGMP ]]>
TwitterFacebookLinkedIn